专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007080392A3 LIGANDS THAT HAVE BINDING SPECIFICITY FOR VEGF AND/OR EGFR AND METHODS OF USE THEREFOR 审中-公开
标题翻译：对VEGF和/或EGFR具有结合特异性的配体及其使用方法
公开(公告)号：WO2007080392A3
公开(公告)日：2007-11-29
申请号：PCT/GB2007000049
申请日：2007-01-10
申请人： DOMANTIS LTD , IGNATOVICH OLGA , HOLMES STEVE , BECKMANN ROLAND , DE WILDT RUDOLF M T , SEPP ARMIN
发明人： IGNATOVICH OLGA , HOLMES STEVE , BECKMANN ROLAND , DE WILDT RUDOLF M T , SEPP ARMIN
IPC分类号： C07K16/22 , A61K39/395 , A61P35/00 , C07K16/24 , C07K16/28
CPC分类号： C07K16/22 , A61K47/6845 , A61K47/6879 , A61K2039/505 , C07K16/18 , C07K16/241 , C07K16/2863 , C07K16/40 , C07K2317/31 , C07K2317/55 , C07K2317/569 , C07K2317/622 , C07K2317/76 , C07K2319/00
摘要： Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described.
摘要翻译：公开了对血管内皮生长因子（VEGF），表皮生长因子受体（EGFR）或VEGF和EGFR具有结合特异性的配体。还公开了使用这些配体的方法。具体而言，描述了这些配体用于癌症治疗的用途。

2. 发明申请

WO2007085815A3 LIGANDS THAT BIND IL-4 AND/OR IL-13 审中-公开
标题翻译：结合IL-4和/或IL-13的配体
公开(公告)号：WO2007085815A3
公开(公告)日：2007-11-15
申请号：PCT/GB2007000228
申请日：2007-01-24
申请人： DOMANTIS LTD , TOMLINSON IAN , STOOP ADRIAN ALLART , SEPP ARMIN , DE SILVA INUSHA , DIMECH CAROLINE J , PUPECKA MALGORZATA , DE WILDT RUDOLF M T , DREW PHILIP D , HOLMES STEVE
发明人： TOMLINSON IAN , STOOP ADRIAN ALLART , SEPP ARMIN , DE SILVA INUSHA , DIMECH CAROLINE J , PUPECKA MALGORZATA , DE WILDT RUDOLF M T , DREW PHILIP D , HOLMES STEVE
IPC分类号： C07K16/24 , A61K39/395 , A61P37/08
CPC分类号： C07K16/247 , A61K2039/505 , A61K2039/507 , C07K16/244 , C07K2317/31 , C07K2317/569
摘要： Disclosed are ligands that have binding specificity for interleukin-4 (IL-4), for interleukin-13 (IL-13), or for IL-4 and IL-13. Also disclosed are methods of using these ligands. In particular, the use of these ligands for treating allergic asthma is described.
摘要翻译：公开了对白细胞介素-4（IL-4），白细胞介素-13（IL-13）或IL-4和IL-13具有结合特异性的配体。还公开了使用这些配体的方法。具体而言，描述了这些配体用于治疗变应性哮喘的用途。

3. 发明申请

WO2007085815A8 LIGANDS THAT BIND IL-4 AND/OR IL-13 审中-公开
标题翻译：绑定IL-4和/或IL-13的配体
公开(公告)号：WO2007085815A8
公开(公告)日：2008-07-31
申请号：PCT/GB2007000228
申请日：2007-01-24
申请人： DOMANTIS LTD , TOMLINSON IAN , STOOP ADRIAAN ALLART , SEPP ARMIN , DE SILVA INUSHA , DIMECH CAROLINE J , PUPECKA MALGORZATA , DE WILDT RUDOLF M T , DREW PHILIP D , HOLMES STEVE
发明人： TOMLINSON IAN , STOOP ADRIAAN ALLART , SEPP ARMIN , DE SILVA INUSHA , DIMECH CAROLINE J , PUPECKA MALGORZATA , DE WILDT RUDOLF M T , DREW PHILIP D , HOLMES STEVE
IPC分类号： C07K16/24 , A61K39/395 , A61P37/08
CPC分类号： C07K16/247 , A61K2039/505 , A61K2039/507 , C07K16/244 , C07K2317/31 , C07K2317/569
摘要： Disclosed are ligands that have binding specificity for interleukin-4 (IL-4), for interleukin-13 (IL-13), or for IL-4 and IL-13. Also disclosed are methods of using these ligands. In particular, the use of these ligands for treating allergic asthma is described.
摘要翻译：公开了对白细胞介素-4（IL-4），白细胞介素-13（IL-13）或IL-4和IL-13具有结合特异性的配体。还公开了使用这些配体的方法。特别地，描述了这些配体用于治疗过敏性哮喘的用途。

4. 发明申请

WO2007049017A2 TUMOR NECROSIS FACTOR RECEPTOR 1 ANTAGONISTS FOR TREATING RESPIRATORY DISEASES 审中-公开
标题翻译：肿瘤坏死因子受体1治疗呼吸道疾病的拮抗剂
公开(公告)号：WO2007049017A2
公开(公告)日：2007-05-03
申请号：PCT/GB2006003935
申请日：2006-10-23
申请人： DOMANTIS LTD , ARGENTA DISCOVERY LTD , DE WILDT RUDOLF M T , HOLMES STEVE , TOMLINSON IAN M , WINTER GREGORY P , FITZGERALD MARY F , FOX JUSTIAN CRAIG , SEPP ARMIN , LEE JENNIFER , WOOLVEN BENJAMIN P
发明人： DE WILDT RUDOLF M T , HOLMES STEVE , TOMLINSON IAN M , WINTER GREGORY P , FITZGERALD MARY F , FOX JUSTIAN CRAIG , SEPP ARMIN , LEE JENNIFER , WOOLVEN BENJAMIN P
IPC分类号： A61K39/00 , C07K16/28
CPC分类号： C07K16/2875 , A61K9/0043 , A61K9/007 , A61K39/3955 , C07K16/28 , C07K16/2878 , C07K2317/31 , C07K2317/569 , C07K2317/76
摘要： Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFRl for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g., inhaler, intranasal delivery device) for the treatment or prevention of lung inflammation or a respiratory disease, and a delivery device for the treatment or prevention of lung inflammation or a respiratory disease that contains an agent as described herein.
摘要翻译：公开了结合肺组织中的靶标以制备用于局部递送至肺组织的长效或长治疗窗口制剂的试剂（例如，抗体片段，拮抗剂，配体，dAb单体）的用途，以及用于施用将肺组织中的靶标结合到受试者以在肺组织中产生长治疗窗口的试剂。该制剂用于，并且该方法包括局部给予肺组织。还公开了TNFR1的拮抗剂在制备用于治疗，预防或抑制肺部炎症或呼吸系统疾病的制剂或药物中的用途，以及治疗这些疾病的方法。还公开了使用试剂a来制造用于治疗或预防肺部炎症或呼吸系统疾病的输送装置（例如，吸入器，鼻内递送装置），以及用于治疗或预防肺部炎症或包含本文所述的药剂的呼吸系统疾病。

5. 发明申请

WO2006038027A3 SINGLE DOMAIN ANTIBODIES AGAINST TNFRl AND METHODS OF USE THEREFOR 审中-公开
标题翻译：针对TNFR1的单一抗体抗体及其使用方法
公开(公告)号：WO2006038027A3
公开(公告)日：2007-01-04
申请号：PCT/GB2005003873
申请日：2005-10-07
申请人： DOMANTIS LTD , BREWIS NEIL D , WOOLVEN BENJAMIN P , HOLMES STEVE , TOMLINSON IAN M , LEE JENNIFER , ENEVER CAROLYN , BASRAN AMRIK , JONES KATE , WILDT RUUD DE , TUNA MIHRIBAN
发明人： BREWIS NEIL D , WOOLVEN BENJAMIN P , HOLMES STEVE , TOMLINSON IAN M , LEE JENNIFER , ENEVER CAROLYN , BASRAN AMRIK , JONES KATE , WILDT RUUD DE , TUNA MIHRIBAN
IPC分类号： A61K39/395 , C07K16/18 , C07K16/24 , C07K16/28 , C07K16/40 , C12N15/13 , C12N15/62 , C12N15/63
CPC分类号： C07K16/18 , A61K47/60 , A61K2039/505 , C07K16/241 , C07K16/2866 , C07K16/2878 , C07K16/40 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/35 , C07K2317/40 , C07K2317/53 , C07K2317/55 , C07K2317/56 , C07K2317/569 , C07K2317/622 , C07K2317/626 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C12N2799/021
摘要： The invention provides methods for treating inflammatory diseases (e.g., chronic inflammatory diseases) comprising administering an antagonist of Tumor Necrosis Factor Receptor 1. The invention also provides ligands that contain an immunoglobulin single variable domain (domain antibody, dAb) monomer that binds Tumor Necrosis Factor Receptor 1, and methods of using the ligands. Also provided are nucleic acids encoding the ligands, recombinant host cells and methods for preparing the ligands.
摘要翻译：本发明提供了治疗炎性疾病（例如慢性炎性疾病）的方法，其包括施用肿瘤坏死因子受体1拮抗剂。本发明还提供了含有结合肿瘤坏死因子的免疫球蛋白单可变结构域（结构域抗体，dAb）单体的配体受体1以及使用配体的方法。还提供了编码配体的核酸，重组宿主细胞和制备配体的方法。

6. 发明申请

WO2010007376A3 COMPOSITIONS MONOVALENT FOR CD28 BINDING AND METHODS OF USE 审中-公开
标题翻译： CD28结合的组合物单一使用方法和使用方法
公开(公告)号：WO2010007376A3
公开(公告)日：2010-05-27
申请号：PCT/GB2009001762
申请日：2009-07-17
申请人： DOMANTIS LTD , ENEVER CAROLYN , GRANT STEVEN , SANSOM DAVID , HOLMES STEVE
发明人： ENEVER CAROLYN , GRANT STEVEN , SANSOM DAVID , HOLMES STEVE
IPC分类号： C07K16/28 , A61K39/395 , A61P37/06
CPC分类号： C07K16/2818 , C07K2317/21 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/76
摘要： The disclosure relates to a monovalent polypeptide domain which specifically binds CD28, as well as to an antagonist of CD28, where the antagonist comprises a monovalent polypeptide domain which specifically binds CD28. This disclosure encompasses monovalent polypeptide domains comprising an antibody single variable domain that monovalently binds CD28. An antibody single variable domain that is monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a monovalent anti-CD28 antibody single variable domain consists of or comprises an antibody single variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the monovalent anti-CD28 antibody single variable domain is a human antibody single variable domain. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a monovalent anti-CD28 antibody single variable domain to the individual.
摘要翻译：本公开涉及特异性结合CD28的单价多肽结构域以及CD28拮抗剂，其中拮抗剂包含特异性结合CD28的单价多肽结构域。本公开内容涵盖包含单价结合CD28的抗体单可变结构域的单价多肽结构域。用于结合CD28的单价抗体单可变区可抑制CD28活性。在一个方面，单价抗CD28抗体单可变结构域由一个方面组成或包含特异性结合和拮抗CD28的活性的抗体单可变结构域，而不具有实质上激动的CD28活性。另一方面，单价抗CD28抗体单可变结构域是人抗体单可变结构域。本公开还包括在个体中拮抗CD80和/或CD86相互作用的方法以及涉及CD80和/或CD86与CD28相互作用的疾病或病症的方法，涉及向单克隆抗CD28抗体单可变结构域施用的方法个人。

7. 发明申请

WO2007066109A8 BISPECIFIC LIGANDS WITH BINDING SPECIFICITY TO CELL SURFACE TARGETS AND METHODS OF USE THEREFOR 审中-公开
标题翻译：具有细胞表面目标的结合特异性的双重配体及其使用方法
公开(公告)号：WO2007066109A8
公开(公告)日：2008-07-17
申请号：PCT/GB2006004565
申请日：2006-12-05
申请人： DOMANTIS LTD , DE ANGELIS ELENA , HOLMES STEVE , TOMLINSON IAN M , HUANG ERIC YI-CHUN , HOLT LUCY J , EVERETT CLAIRE E
发明人： DE ANGELIS ELENA , HOLMES STEVE , TOMLINSON IAN M , HUANG ERIC YI-CHUN , HOLT LUCY J , EVERETT CLAIRE E
IPC分类号： C07K16/28 , A61K38/02 , C07K16/30
CPC分类号： C07K16/2803 , A61K47/6817 , A61K47/6843 , A61K47/6849 , A61K47/6853 , A61K2039/505 , C07K16/2896 , C07K16/3007 , C07K2317/31 , C07K2317/569 , C07K2317/77
摘要： Disclosed are ligands comprising a first polypeptide domain having a binding site with binding specificity for a first cell surface target and a second polypeptide domain having a binding site for a second cell surface target, wherein each target are different and on the same cell. In some embodiments, the ligands described further comprise a toxin. In other embodiments, the ligands further comprise half-life extending moieties. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described.
摘要翻译：公开了包含具有对第一细胞表面靶具有结合特异性的结合位点的第一多肽结构域和具有第二细胞表面靶的结合位点的第二多肽结构域的配体，其中每个靶在不同的同一细胞上。在一些实施方案中，所描述的配体还包含毒素。在其它实施方案中，配体还包含半衰期延长部分。也公开了使用这些配体的方法。特别地，描述了这些配体用于癌症治疗的用途。

8. 发明申请

WO2006059106A3 BISPECIFIC DOMAIN ANTIBODIES TARGETING SERUM ALBUMIN AND GLP-1 OR PYY 审中-公开
标题翻译：靶向血清ALBUMIN和GLP-1或PYY的双重抗体
公开(公告)号：WO2006059106A3
公开(公告)日：2007-01-04
申请号：PCT/GB2005004599
申请日：2005-11-30
申请人： DOMANTIS LTD , HOLMES STEVE , HOLT LUCY J , JESPERS LAURENT S , TOMLINSON IAN M
发明人： HOLMES STEVE , HOLT LUCY J , JESPERS LAURENT S , TOMLINSON IAN M
IPC分类号： C07K16/46 , A61K47/48 , A61P1/00 , A61P3/10 , C07K16/44
CPC分类号： C12N15/62 , A61K38/00 , A61K39/3955 , A61K47/6811 , A61K47/6843 , C07K14/70578 , C07K14/7155 , C07K16/44 , C07K2317/569 , C07K2318/10 , C07K2318/20 , C07K2319/00 , C07K2319/31
摘要： Drug fusions and conjugates that contain an incretin therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The conjugates and fusion have a longer in vivo half life in comparison with the unconjugated or unfused therapeutic or diagnostic agent.
摘要翻译：药物融合物和缀合物，其含有与结合血清白蛋白的抗体的抗原结合片段融合或缀合的肠促胰岛素治疗剂或诊断剂。与非共轭或未融合的治疗或诊断剂相比，缀合物和融合物具有比体内较长的体内半衰期。

9. 发明申请

WO2010033342A3 SCANNING MIRROR CONTROL 审中-公开
标题翻译：扫描镜子控制
公开(公告)号：WO2010033342A3
公开(公告)日：2010-06-03
申请号：PCT/US2009054654
申请日：2009-08-21
申请人： MICROVISION INC , HOLMES STEVE , ROLLINS CLINT CHARLES , BROWN MARGARET K , SCHAAF MICHAEL LEE , ROTHAAR BRUCE C , JACKSON ROBERT JAMES , MCLAUCHLAN LIFFORD , MEHRUBEOGLU MEHRUBE , SCHNEIDER GREGORY
发明人： HOLMES STEVE , ROLLINS CLINT CHARLES , BROWN MARGARET K , SCHAAF MICHAEL LEE , ROTHAAR BRUCE C , JACKSON ROBERT JAMES , MCLAUCHLAN LIFFORD , MEHRUBEOGLU MEHRUBE , SCHNEIDER GREGORY
IPC分类号： G02B26/08
CPC分类号： G02B26/121 , G05B13/024 , H02K41/0354 , H02P29/50
摘要： A scanning beam projection system (100) includes a scanning mirror (116) having a fast-scan axis and a slow-scan axis. Movement on the slow-scan axis is controlled by a slow-scan scanning mirror control system (130). The control system receives position information describing angular displacement of the mirror. An outer loop of the control system operates in the frequency domain and determines harmonic drive coefficients for a scanning mirror drive signal. An inner loop of the control system operates in the time domain and compensates for a scanning mirror resonant vibration mode at a frequency within the frequency band occupied by the harmonic drive coefficients.
摘要翻译：扫描光束投影系统（100）包括具有快速扫描轴和慢速扫描轴的扫描镜（116）。慢扫描轴上的移动由慢扫描扫描镜控制系统（130）控制。控制系统接收描述反射镜的角位移的位置信息。控制系统的外环在频域中操作并确定扫描镜驱动信号的谐波驱动系数。控制系统的内环在时域中操作并且补偿谐波驱动系数占用的频带内的频率处的扫描镜共振模式。

10. 发明申请

WO2011012609A3 ANTI - TGF - BETA RECEPTOR TYPE II SINGLE DOMAIN ANTIBODIES 审中-公开
标题翻译：抗TGF - β受体II型单个抗体
公开(公告)号：WO2011012609A3
公开(公告)日：2011-09-15
申请号：PCT/EP2010060867
申请日：2010-07-27
申请人： GLAXO GROUP LTD , DE WILDT RUDOLF MARIA , DIMECH CAROLINE J , HOLMES STEVE , STOOP ADRIAAN ALLART
发明人： DE WILDT RUDOLF MARIA , DIMECH CAROLINE J , HOLMES STEVE , STOOP ADRIAAN ALLART
IPC分类号： C07K16/28 , A61P27/02 , A61P43/00 , C07K16/40
CPC分类号： C07K16/2863 , C07K16/40 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/76 , C07K2317/92
摘要： The invention provides an anti-TGFbetaRII immunoglobulin single variable domain. Suitably, an anti-TGFbetaRII immunoglobulin single variable domain in accordance with the invention is one which binds to TGFbetaRII with a dissociation constant (Kd) in the range of 10pM to 50nM, preferably 10pM to 10nM, preferably 250pM to 10nM. Isolated polypeptides comprising an amino acid sequence that is at least 70% identical to at least one amino acid sequence selected from the group of: SEQ ID NOs: 1 to 23, wherein said isolated polypeptide binds to TGFbetaRII are also provided. The invention also provides a polypeptide, ligand or pharmaceutical composition for treating a disease associated with TGFbeta signalling and suitably a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis, liver fibrosis, including cirrhosis and chronic hepatitis, rheumatoid arthritis, ocular disorders, or fibrosis of the skin, including keloid of skin, and kidney such as nephritis, kidney fibrosis and nephrosclerosis, and a vascular condition, such as restenosis.
摘要翻译：本发明提供抗TGFbetaRII免疫球蛋白单可变结构域。适当地，根据本发明的抗TGFbetaRII免疫球蛋白单可变结构域是以解离常数（Kd）在10pM至50nM，优选10pM至10nM，优选250pM至10nM范围内结合TGFbetaRII的结合。分离的多肽包含与选自SEQ ID NO：1至23的至少一个氨基酸序列至少70％相同的氨基酸序列，其中所述分离的多肽与TGFbetaRII结合。本发明还提供了用于治疗与TGFbeta信号传导相关疾病的合适的多肽，配体或药物组合物，适当地选自以下组中的疾病：组织纤维化，例如肺纤维化，包括特发性肺纤维化，肝纤维化，包括肝硬化和慢性肝炎，类风湿性关节炎，眼部疾病或皮肤纤维化，包括皮肤瘢痕疙瘩，肾脏如肾炎，肾纤维化和肾硬化，以及血管病变，如再狭窄。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式